Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin, Capecitabine, and Cetuximab in Advanced Gastric or Gastroesophageal Cancer
NCT00183898Phase 2Completed
- Sponsor
- University of Southern California
- Start
- Dec 2004
- Primary completion
- Feb 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, capecitabine and KL-140 in gastric cancer (GC) and esophageal cancer, sponsored by University of Southern California. Primary endpoint: Rate of Progression-Free Survival at 4 months. Started Dec 2004; status: completed.
02
Drugs
oxaliplatincapecitabineKL-140
03
Conditions
gastric cancer (GC)esophageal cancer
Beyond the preview
Go deeper on NCT00183898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00183898.